Argenx to unveil its ‘vision 2030: taking breakthrough science to 50,000 patients' during its upcoming r&d day on july 16, 2024

R&d day presentations to include recent phase 2 datasets in sjogren's disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to phase 3 development

ARGX Ratings Summary

ARGX Quant Ranking